Product Description
For Hypercholesterolemia (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00404001)
Mechanisms of Action: Cholesterol Absorption Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Ironwood
Company Location: BOSTON MA 02110
Company CEO: Thomas McCourt
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Hypercholesterolemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
MCP-104-201 | P2 |
Completed |
Hypercholesterolemia |
None |